Skip to main content

Advertisement

SpringerLink
Log in

Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background

Plasma microRNA (miRNA) levels may be altered during pathological processes; therefore, they may potentially serve as biomarkers for the diagnosis and prognosis of human diseases. This study aimed to explore whether plasma miRNAs may serve as new biomarkers for liver injury among chronic hepatitis B (CHB) patients with normal or nearly normal alanine aminotransferase (ALT) levels.

Methods

Plasma miRNAs from each of three independent groups (no prominent liver injury and persistently normal ALT levels, NPNALT; significant liver injury with persistently normal ALT levels, SPNALT; and healthy) were profiled by miRNA microarray analysis. Differentially expressed miRNAs were then validated by a quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay. The area under the receiver operating characteristic (AUC) curve was used to analyze the candidate miRNAs validated by qRT-PCR for diagnostic accuracy.

Results

Twenty differentially expressed miRNAs were identified by microarray analysis. Seven miRNAs with elevated serum levels were validated by qRT-PCR analysis, and four of them were significantly different between the SPNALT and NPNALT groups. The AUCs of hsa-miR-122-5p and hsa-miR-151-3p were 0.877 (cutoff value = 13.38; 95% CI 0.792–0.963; sensitivity = 83.3%, specificity = 80%) and 0.882 (cutoff value = 7.4; 95% CI 0.797–0.966; sensitivity = 83.3%, specificity = 73.3%), respectively, indicating early liver injury. However, there was no significant correlation of miRNAs with either necroinflammation or fibrosis.

Conclusion

Serum hsa-miR-122-5p and hsa-miR-151-3p may function as new biomarkers for liver injury in SPNALT patients. With these two biomarkers, we may be able to identify a subset of patients who are experiencing liver injury but have normal ALT levels for further evaluation with a biopsy procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010;14:381–396.

    Article  PubMed  Google Scholar 

  2. Nguyen LH, Chao D, Lim JK, Ayoub W, Nguyen MH. Histologic changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 2014;12:1262–1266.

    Article  PubMed  CAS  Google Scholar 

  3. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376–1384.

    Article  PubMed  Google Scholar 

  4. Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007;45:1193–1198.

    Article  PubMed  CAS  Google Scholar 

  5. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010;11:252–263.

    Article  PubMed  CAS  Google Scholar 

  6. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597–610.

    Article  PubMed  CAS  Google Scholar 

  7. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011;54:1767–1776.

    Article  PubMed  CAS  Google Scholar 

  8. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012;56:1946–1957.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Grady WM, Tewari M. The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut 2010;59:706–708.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110:483–495.

    Article  PubMed  CAS  Google Scholar 

  11. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997–1006.

    Article  PubMed  CAS  Google Scholar 

  12. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106:4402–4407.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–435.

    Article  PubMed  CAS  Google Scholar 

  14. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699.

    Article  PubMed  CAS  Google Scholar 

  15. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res 2014;42:D78–D85.

    Article  PubMed  CAS  Google Scholar 

  16. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 2008;14:1012–1017.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 2008;24:325–332.

    Article  PubMed  CAS  Google Scholar 

  18. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, et al. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 2006;7:59.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Wang Y, Liang J, Qin H, Ge Y, Du J, Lin J, et al. Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE. Arthritis Res Ther 2016;18:263.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Pu XY, Shen JY, Deng ZP, Zhang ZA. Plasma-specific microRNA response induced by acute exposure to aristolochic acid I in rats. Arch Toxicol 2017;91:1473–1483.

    Article  PubMed  CAS  Google Scholar 

  21. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011;6:e23937.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198–201.

    Article  PubMed  CAS  Google Scholar 

  23. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 2010;6:402.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Xing TJ, Jiang DF, Huang JX, Xu ZL. Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver disease. Genet Mol Res 2014;13:7912–7918.

    Article  PubMed  CAS  Google Scholar 

  25. Zhang X, Zhang Z, Dai F, Shi B, Chen L, Zhang X, et al. Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C. PLoS One 2014;9:e92112.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Arataki K, Hayes CN, Akamatsu S, Akiyama R, Abe H, Tsuge M, et al. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol 2013;85:789–798.

    Article  PubMed  CAS  Google Scholar 

  27. Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012;19:e58–e65.

    Article  PubMed  CAS  Google Scholar 

  28. Baumert TF, Thimme R, von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007;13:82–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Tan Y, Ge G, Pan T, Wen D, Gan J. Serum MiRNA panel as potential biomarkers for chronic hepatitis B with persistently normal alanine aminotransferase. Clin Chim Acta 2015;451:232–239.

    Article  PubMed  CAS  Google Scholar 

  30. Lai S, Yuan J, Zhao D, Shen N, Chen W, Ding Y, et al. Regulation of mice liver regeneration by early growth response-1 through the GGPPS/RAS/MAPK pathway. Int J Biochem Cell Biol 2015;64:147–154.

    Article  PubMed  CAS  Google Scholar 

  31. Lin X, Bai F, Nie J, Lu S, Lu C, Zhu X, et al. Didymin alleviates hepatic fibrosis through inhibiting ERK and PI3K/Akt pathways via regulation of Raf kinase inhibitor protein. Cell Physiol Biochem 2016;40:1422–1432.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the National Science and Technology Major Project (2012ZX10002004-001) and the Science Fund for Creative Research Groups of the National Natural Science Foundation of China (No. 81121002).

Author information

Authors and Affiliations

  1. State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China

    Jin-Lin Cheng, Shi-Gui Yang, Er-Mei Chen, Wen-Qian Chen & Lan-Juan Li

  2. Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China

    Hong Zhao

Authors
  1. Jin-Lin Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shi-Gui Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Er-Mei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wen-Qian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lan-Juan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lan-Juan Li.

Ethics declarations

Conflict of interest

Jin-Lin Cheng, Hong Zhao, Shi-Gui Yang, Er-Mei Chen, Wen-Qian Chen, Lan-Juan Li declare that they have no conflicts of interest.

Ethical approval

This was a prospective study conducted at the First Affiliated Hospital, Medical College of Zhejiang University. The study protocol was reviewed and approved by the Ethics Committee of the First Affiliated Hospital, Medical College of Zhejiang University, and all experiments were carried out in accordance with the relevant guidelines and regulations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheng, JL., Zhao, H., Yang, SG. et al. Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT. Hepatol Int 12, 277–287 (2018). https://doi.org/10.1007/s12072-018-9871-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-018-9871-0

Keywords

Search

Navigation